AMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
AMARIN CORP PLC\UK
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$11.53+0.21 (+1.86%)
Close on Oct 19, 2026
- Market cap
- $4.80B
- P/E (TTM)
- –
- Dividend yield
- –
AMARIN CORP PLC\UK revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue, Net | $177.50M | $185.04M | $182.75M | $196.28M | $189.57M | $190.47M | $204.59M | $215.08M | $238.13M | $255.80M | $285.30M | $304.25M | 95.3% | -6.4% |
| Licensing and Royalty Revenue | $8.73M | $31.72M | $30.89M | $30.46M | $29.79M | $23.64M | $24.02M | $25.94M | $26.65M | $21.65M | $21.61M | $18.19M | 4.7% | -70.7% |
By region
From the segment and revenue-disaggregation notes of Amarin Corp Plc\Uk's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.